Showing 2241-2250 of 5623 results for "".
- Penn Medicine Neuroscientists Identify Brain Mechanism that Drives Focus Despite Distractionshttps://modernod.com/news/penn-medicine-neuroscientists-identify-brain-mechanism-that-drives-focus-despite-distractions/2481770/In a new study published in Neuron, neuroscientists in the Perelman School of Medicine at the University of Pennsylvania sought to illuminate the neural mechanism that helps the brain decide whether to focus visual
- Kodiak Discontinues Further Development of Tarcocimab After Phase 3 Trial Datahttps://modernod.com/news/kodiak-discontinues-further-development-of-tarcocimab-after-phase-3-trial-data/2481748/Kodiak Sciences has announed it discontinuing further development of tarcocimab tedromer, a novel antibody biopolymer conjugate, being evaluated for wet AMD and DME. The decision comes after the GLEAM and GLIMMER studies failed to meet their primary efficacy endpoints. Th
- FDA Approves Xdemvy, First Treatment for Demodex Blepharitishttps://modernod.com/news/fda-approves-xdemvy-first-treatment-for-demodex-blepharitis/2481743/The FDA has approved Tarsus Pharmaceuticals' Xdemvy (lotilaner ophthalmic solution 0.25%) for the treatment of Demodex blepharitis. Xdemvy, formerly known as TP-03, is the first and only FDA approved treatment to directly target Demodex mites, the root cause
- FDA Accepts DORC’s Orphan-Drug Designation Application for Trypan Blue and Brilliant Blue Ghttps://modernod.com/news/fda-accepts-dorcs-orphan-drug-designation-application-for-trypan-blue-and-brilliant-blue-g/2481740/DORC has has received notification from the FDA that their application for orphan drug designation for a dual combination of Trypan Blue and Brilliant Blue G ophthalmic solutions has been granted. DORC's MembraneBlue-Dual ILM and ERM stain has been used in more than 500,00
- OcuTerra Completes Enrollment in Phase 2 DR:EAM Trial of Topically Delivered OTT166 in Adults with Diabetic Retinopathyhttps://modernod.com/news/ocuterra-completes-enrollment-in-phase-2-dream-trial-of-topically-delivered-ott166-in-adults-with-diabetic-retinopathy/2481732/OcuTerra Therapeutics announced full enrollment in the company’s phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe nonproliferative diabeti
- Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Noregen for Retinal Diseaseshttps://modernod.com/news/caeregen-therapeutics-receives-14-million-phase-2-sbir-grant-from-nihnei-to-advance-development-of-regenerative-medicine-clinical-candidate-ctr-107-noregen-for-retinal-diseases/2481729/Caeregen Therapeutics announced that it has been awarded a $1.4 million phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen), a regenerative therapeutic for the treatme
- Smartlens Closes $6.1 Million Series A Financing to Advance miLens Devicehttps://modernod.com/news/smartlens-closes-61-million-series-a-financing-to-advance-milens/2481727/Smartlens has closed an oversubscribed $6.1 million Series A equity financing round to advance regulatory clearance for miLens, a novel, electronics-free, soft contact lens for monitoring diurnal IOP. The miLens device is an electronics free soft contact lens that uses mi
- Dean Burns Named President and CEO of Ocumeticshttps://modernod.com/news/dean-burns-named-president-and-ceo-of-ocumetics/2481722/Ocumetics Technology has appointed ophthalmic executive Dean Burns as President and CEO. Mr. Burns, whoj will also join the Ocumetics board of directors, was previously a consultant for Ocumetics, assisting with regulatory and marketing endeavours. Mr. Burns replaces 
- Nacuity Pharmaceuticals Advances Phase 1/2 Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progressionhttps://modernod.com/news/nacuity-pharmaceuticals-advances-phase-12-trial-evaluating-npi-002-intravitreal-implant-for-the-delay-of-cataract-progression/2481719/Nacuity Pharmaceuticals announced that a clinical trial site has been added to its phase 1/2 clinical trial evaluating NPI-002, a proprietary antioxidant molecule delivered via a sustained release intravitreal implant, for the delay of cataract progression in patients undergoing vitrectomy.
- Nicox Presents NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis at the World Glaucoma Congresshttps://modernod.com/news/nicox-presents-ncx-470-phase-3-mont-blanc-adaptive-design-data-and-additional-subset-analysis-at-the-world-glaucoma-congress/2481705/Nicox presented additional data on NCX 470 at the 10th World Glaucoma Congress (WGC) in Rome, Italy. “The large volume of data generated in the Mont Blanc phase 3 trial on NCX 470 has provided us with the opportunity to look in detail at patient subgroups to further